A simulation study of the cost of cerebral vasospasm treatments with clazosentan: A mathematical model using time-driven activity-based costing
Open Access
- 2 January 2026
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (1) , e0340076
Abstract
In this work, we aimed to assess the impact of clazosentan on clinical labour time costs within Japan’s value-based healthcare system using time-driven activity-based costing. Time-driven activity-based costing was employed to analyse the labour time costs associated with preventing cerebral vasospasm following aneurysmal subarachnoid haemorrhage. Time-driven activity-based costing simplifies cost analysis by utilising time as the primary cost driver. We compared two treatment approaches: conventional therapy with fasudil hydrochloride and postoperative therapy with clazosentan. Scenario and sensitivity analyses were performed to assess the impact of physicians’ costs on the results. The use of clazosentan for the prevention of cerebral vasospasm significantly reduced human resource costs, particularly in cases where symptomatic vasospasm did not occur, yielding savings of approximately 51,343 yen. The greatest cost reductions were observed among nursing staff, with a 30% decrease in the absence of symptomatic vasospasm and a 15% reduction when symptomatic vasospasm was present. The cost reductions for physicians were comparatively smaller, particularly in cases where symptomatic vasospasm occurred. Sensitivity analyses indicated that clazosentan reduced overall costs by approximately 35,000–50,000 yen; however, costs increased in the presence of symptomatic vasospasm. Clazosentan for subarachnoid haemorrhage treatment significantly reduces human resource costs, especially in nursing staff. These findings support the potential of clazosentan for broader clinical use, given its cost-savings and clinical benefits in reducing cerebral vasospasm following aneurysmal subarachnoid haemorrhage.Keywords
This publication has 14 references indexed in Scilit:
- Effects of clazosentan on cerebral vasospasm–related morbidity and all-cause mortality after aneurysmal subarachnoid hemorrhage: two randomized phase 3 trials in Japanese patientsJournal of Neurosurgery, 2022
- World Stroke Organization (WSO): Global Stroke Fact Sheet 2022International Journal of Stroke, 2022
- Twenty-Year Change in Severity and Outcome of Ischemic and Hemorrhagic StrokesJAMA Neurology, 2021
- Probabilistic time‐driven activity‐based costingJournal of Corporate Accounting & Finance, 2020
- An 8-step framework for implementing time-driven activity-based costing in healthcare studiesThe European Journal of Health Economics, 2019
- Time-driven activity-based costing in health care: A systematic review of the literatureHealth Policy, 2017
- Preventive Effect of Clazosentan against Cerebral Vasospasm after Clipping Surgery for Aneurysmal Subarachnoid Hemorrhage in Japanese and Korean PatientsCerebrovascular Diseases, 2017
- Time-driven activity-based costing to identify opportunities for cost reduction in pediatric appendectomyJournal of Pediatric Surgery, 2016
- Rethinking the cost of healthcare in low-resource settings: the value of time-driven activity-based costingBMJ Global Health, 2016
- Measuring the cost of care in benign prostatic hyperplasia using time-driven activity-based costing (TDABC)Healthcare, 2015